<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the relationship between <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and endothelial function in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients with or without <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and to explore the pathophysiological mechanisms of the increased macrovascular risk in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Twelve type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (urinary albumin 30-300 g/mg <z:chebi fb="0" ids="16737">creatinine</z:chebi>, DM-MA) and 12 type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients without <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (urinary albumin &lt;30 g/mg <z:chebi fb="0" ids="16737">creatinine</z:chebi>, DM-NA) were recruited, matched for their sex, age, body mass index (BMI), <z:mp ids='MP_0002055'>diabetes</z:mp> duration, <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Their <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (HbA1C) was less than 7.5% and the blood pressure was lower than 140/90 mmHg </plain></SENT>
<SENT sid="3" pm="."><plain>None had evidence of macrovascular disease and serum cholesterol levels were <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Twelve healthy volunteers (C) were enrolled as controls </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects received a hyperinsulinemic euglycemic clamp study (insulin infusion rate, 120 mU/m2/min) to assess the peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal rate (GDR) in the steady state and had a high-resolution ultrasonography to measure vasodilation in the brachial artery diameter in response to reactive hyperemia (endothelium-dependent) and administration of <z:chebi fb="2" ids="24364">glyceryl</z:chebi> trinitrate (endothelium-independent) </plain></SENT>
<SENT sid="6" pm="."><plain>Plasma free fatty acids (FFAs), plasminogen activator inhibitor type I (PAI-1), and <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWF) were also measured </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The GDR was lower in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (7.90 +/- 1.79 mg/kg/min) than in patients without <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (9.46 +/- 1.59 mg/kg/min, P&lt;0.05), and the GDR in both <z:mp ids='MP_0002055'>diabetes</z:mp> groups was decreased, compared with the findings from the healthy control group (13.06 +/- 1.98 mg/kg/min, P&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma FFAs concentration was different among the three groups (DM-MA-1008 +/- 229 mol/l, DM-NA-675 +/- 201 mol/l, P&lt;0.01; C-364 +/- 169 mol/l, P&lt;0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>Endothelium-dependent vasodilation was impaired in the microalbuminuric patients (8.0 +/- 3.8%) compared with the normoalbuminuria patients (9.7 +/- 4.3%, P&gt;0.05) and the healthy controls (14.2 +/- 5.0, P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Plasma PAI-1 and vWF levels increased in the microalbuminuric patients (61.9 +/- 18.2 ng/ml, 126.8 (76.5-212.7) %) compared with the levels in the normoalbuminuric patients (45.4 +/- 16.3 ng/ml, 87.9 (84.2-114) %) (PAI-1, P&lt;0.05; vWF, P&gt;0.05) and in the healthy controls (33.6 +/- 10.6 ng/ml, 67.2 (61.5-75.4) %, both P&lt;0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, the partial correlation analysis revealed a significant positive correlation between GDR and endothelium-dependent vasodilation (r=0.465, P&lt;0.01, n=36), and a negative correlation between GDR and plasma FFA levels (P&lt;0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Compared with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients with normoalbuminuria, patients with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> had more severe <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, more prominent <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, and higher plasma FFA, PAI-1, and vWF levels </plain></SENT>
<SENT sid="13" pm="."><plain>Therefore we speculate that <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> may act within the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> to increase the cardiovasular risk in this subset of patients, and improving <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> may reduce the morbidity and mortality from macrovascular complications in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
</text></document>